CSL Limited (CSL.AX)
CSL Limited (CSL.AX) Stock Price, Analysis & Data
| Bid | n/a |
| Market Cap | 75.58B |
| Revenue (ttm) | 15.41B |
| Net Income (ttm) | 1.4B |
| Beta | 0.09 |
| EPS (ttm) | 8.72 |
| PE Ratio (ttm) | 18.1 |
| Forward PE | 16.59 |
| P/B (ttm) | 2.89 |
| P/S (ttm) | 4.91 |
| Earnings Date | Feb 9, 2027 |
| Ask | n/a |
| Volume | 3,698,476 |
| Avg. Volume (20D) | 1,625,497 |
| Open | 148.65 |
| Previous Close | 134.60 |
| Day's Range | 148.41 - 159.25 |
| 52-Week Range | 90.00 - 273.45 |
| Analyst | Buy |
| Price Target | 130.26 (-17.46%) |
| Dividends | $4.26 (3.17%) |
| Ex-Dividend Date | Mar 10, 2026 |
About CSL.AX
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment...
Financial Performance
In 2025, CSL's revenue was 15.43B, an increase of 5.04% compared to the previous year's 14.69B. Earnings were 3B, an increase of 13.63%.
Financial numbers in AUD Financial StatementsAnalyst Forecast
According to 16 analyst ratings, the average rating for CSL.AX stock is "Buy". The 12-month stock price forecast is 130.26, which is downside of 17.46% from the latest price.
Stock ForecastsAnalysts project revenue of ... Upgrade
